111 related articles for article (PubMed ID: 18303446)
1. Immune hemolytic anemia after treatment with pemetrexed for lung cancer.
Park GM; Han KS; Chang YH; Kim CH; Lee JC
J Thorac Oncol; 2008 Feb; 3(2):196-7. PubMed ID: 18303446
[No Abstract] [Full Text] [Related]
2. A case of pemetrexed-induced acute lung injury in non-small cell lung cancer.
Kim HO; Lee SY; Shim JJ; Kang KH; Shin BK
J Thorac Oncol; 2010 Mar; 5(3):401-2. PubMed ID: 20186027
[No Abstract] [Full Text] [Related]
3. Severe immune hemolytic anemia due to pemetrexed in a patient with non-small cell lung cancer.
Sun X; Sheng L; Deng Q; Liu P; Lu K
Pharmacology; 2011; 88(5-6):242-4. PubMed ID: 21997597
[TBL] [Abstract][Full Text] [Related]
4. Pemetrexed induced aseptic meningitis.
Shah BK; O'Keefe S
Acta Oncol; 2012 Mar; 51(3):399-400. PubMed ID: 21936754
[No Abstract] [Full Text] [Related]
5. Pemetrexed-induced hyperpigmentation of the skin.
Schallier D; Decoster L; de Greve J
Anticancer Res; 2011 May; 31(5):1753-5. PubMed ID: 21617235
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed-induced lung toxicity: a case report.
Breuer S; Nechushtan H
Clin Oncol (R Coll Radiol); 2012 Feb; 24(1):76-7. PubMed ID: 21924594
[No Abstract] [Full Text] [Related]
7. Pemetrexed and maintenance therapy for non-small cell lung cancer.
Prescrire Int; 2011 Feb; 20(113):39. PubMed ID: 21488588
[No Abstract] [Full Text] [Related]
8. Pemetrexed-induced edema of the eyelid.
Kurata T; Tamura K; Okamoto I; Satoh T; Nakagawa K; Fukuoka M
Lung Cancer; 2006 Nov; 54(2):241-2. PubMed ID: 16996165
[TBL] [Abstract][Full Text] [Related]
9. [Study of use of pemetrexed in non-small cell lung cancer].
Villanueva-Herraiz S; Ortega-García MP; Camps-Herrero C; Blasco-Segura P
Farm Hosp; 2010; 34(4):194-203. PubMed ID: 20594885
[TBL] [Abstract][Full Text] [Related]
10. Alveolar hemorrhage associated with pemetrexed administration.
Kurimoto R; Sekine I; Iwasawa S; Sakaida E; Tada Y; Tatsumi K; Takahashi Y; Nakatani Y; Imai C; Takiguchi Y
Intern Med; 2015; 54(7):833-6. PubMed ID: 25832952
[TBL] [Abstract][Full Text] [Related]
11. Interstitial pneumonitis after treatment with pemetrexed: a rare event?
Hochstrasser A; Benz G; Joerger M; Templeton A; Brutsche M; Früh M
Chemotherapy; 2012; 58(1):84-8. PubMed ID: 22377772
[TBL] [Abstract][Full Text] [Related]
12. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Paz-Ares LG; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
J Clin Oncol; 2013 Aug; 31(23):2895-902. PubMed ID: 23835707
[TBL] [Abstract][Full Text] [Related]
13. Kidney tubular toxicity of maintenance pemetrexed therapy.
Glezerman IG; Pietanza MC; Miller V; Seshan SV
Am J Kidney Dis; 2011 Nov; 58(5):817-20. PubMed ID: 21849225
[TBL] [Abstract][Full Text] [Related]
14. Critical acral ischaemia leading to multiple finger amputation: side-effect of long-term (>30 cycles) pemetrexed maintenance treatment in a patient.
Gupta N; Gupta S; Gandhi S; Hatoum H; Dy G
Br J Clin Pharmacol; 2014 Nov; 78(5):1167-8. PubMed ID: 24962715
[No Abstract] [Full Text] [Related]
15. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
Molina JR; Adjei AA
Clin Lung Cancer; 2003 Jul; 5(1):21-7. PubMed ID: 14596699
[TBL] [Abstract][Full Text] [Related]
16. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC
Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221
[TBL] [Abstract][Full Text] [Related]
17. [Safety of pemetrexed mono-therapy in elderly patients with non-small cell lung cancer].
Konishi A; Kitada N; Nanjo S; Tanaka S; Tomii K; Katakami N; Hashida T
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1507-10. PubMed ID: 23064061
[TBL] [Abstract][Full Text] [Related]
18. Acute generalized exanthematous pustulosis after pemetrexed, and recurrence after re-introduction.
Bracke A; Van Marck E; Lambert J
Clin Exp Dermatol; 2009 Apr; 34(3):337-9. PubMed ID: 18699838
[TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed in advanced non-small cell lung cancer.
Gridelli C; Maione P; Rossi A; Bareschino MA; Schettino C; Sacco PC; Zeppa R
Expert Opin Drug Saf; 2011 Mar; 10(2):311-7. PubMed ID: 21261558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]